Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
Clearmind Medicine will be working with Bar-Ilan University in Israel to evaluate the company’s 5-Methoxy-2-aminoindane (MEAI) compound as a potential treatment for addiction and other binge behaviours.
Renowned neuropsychopharmacologist, professor Gal Yadid, an expert in the research and development of treatments for psychiatric disease, specifically drug addiction, depression, and PTSD from the Gonda Multidisciplinary Brain Research Center at the university, will be spearheading the project.
CEO of Clearmind, Adi Zuloff-Shani, Ph.D., commented: “Professor Yadid is a pioneer in the field and I am thrilled that he has agreed to help move our research forward.
“His contributions to the understanding and treatment of addiction inform the work we are doing at Clearmind and I look forward to working with him and his team at Bar Ilan University.”
Professor Yadid and his team will conduct a series of studies to verify the mechanism of action and specific neural targets of MEAI and evaluate its efficacy as a potential therapeutic agent.
Yadid said: “Many conventional treatments for addiction are not effective – some I might argue, are in fact detrimental to recovery.
“My research takes a neuropsychopharmacological approach to treating mental health disorders; once we have identified the altered brain pathways related to a specific condition, I hope we can use compounds like MEAI to manipulate these pathways to help manage or even eliminate the maladapted behaviors.”
Clearmind says that MEAI is a psychoactive molecule that exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages.
[activecampaign form=52]
